Clinical Trials Directory

Trials / Completed

CompletedNCT04503746

A Study to Evaluate the Efficacy and Safety of ALH-L1005 in Patients With Chronic Periodontitis

A Multi-center, Randomized, Double-Blind, Phase II Clinical Trial to Evaluate the Efficacy and Safety of 12-week Treatment of ALH-L1005 600 mg or 1200 mg in Patients With Chronic Periodontitis

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
117 (actual)
Sponsor
AngioLab, Inc. · Industry
Sex
All
Age
18 Years – 78 Years
Healthy volunteers
Not accepted

Summary

The main objective of this study is to evaluate efficacy and safety of ALH-L1005 in patients with chronic periodontitis

Conditions

Interventions

TypeNameDescription
DRUGALH-L1005 600mg/dayALH-L1005 300mg 2 tablet and placebo 2 tablet
DRUGALH-L1005 1,200mg/dayALH-L1005 300mg 4 tablet
DRUGPlaceboPlacebo 4 tablet

Timeline

Start date
2020-07-16
Primary completion
2021-12-13
Completion
2021-12-13
First posted
2020-08-07
Last updated
2022-08-11

Locations

1 site across 1 country: South Korea

Source: ClinicalTrials.gov record NCT04503746. Inclusion in this directory is not an endorsement.

A Study to Evaluate the Efficacy and Safety of ALH-L1005 in Patients With Chronic Periodontitis (NCT04503746) · Clinical Trials Directory